{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-011830","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2025-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.368772+00:00","generated_at":"2026-05-24T23:46:29.419259+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bioventus Q4 revenue $153.6M (+13.5%); FY2025 guidance implies 6-8% organic growth","bullets":["Q4 net loss from cont ops $0.3M vs ($7.7M) prior year; adj EBITDA $28.3M (+28.3%).","FY2024 revenue $573.3M (+11.9%); net loss $43.8M vs ($121.2M); adj EBITDA $108.9M (+22.5%).","FY2025 guidance: net sales $560-570M, adj EBITDA $112-116M, non-GAAP EPS $0.64-$0.68.","Debt reduced by $48.3M in Q4; Advanced Rehabilitation Business divested for $24.7M proceeds.","Pain Treatments and Surgical Solutions each delivered double-digit revenue growth for fifth straight quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-011830","json":"https://secwatch.observer/filing/0001628280-25-011830.json","markdown":"https://secwatch.observer/filing/0001628280-25-011830.md","text":"https://secwatch.observer/filing/0001628280-25-011830.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000162828025011830/0001628280-25-011830-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000162828025011830/bvs-20250311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T23:46:29.419259+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}